Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or the "Company”) today announced that it has received a U.S. patent covering additional aspects of its process for synthesizing halogenated xanthenes, the family of compound to which rose bengal belongs. The patent covers use of certain halogenated xanthenes in pharmaceutical compositions and as medicaments.
Eric Wachter, CTO of Provectus, noted, "U.S. Patent No. 9,422,260 covers claims that we announced in mid-July had been allowed by the U.S. Patent and Trademark Office. It covers subject matter included in the original, 'parent' case that led to issuance of U.S. Patent 8,530,675 in September 2013, covering our novel process for synthesizing rose bengal and related analogs. This ‘daughter’ patent extends protection to use of a wide range of those analogs in or as therapeutic products, and provides complementary protection to that afforded by the parent patent."
Wachter added, "The daughter patent provides a significant potential commercial lifetime for these analogs. Along with U.S. Patent No. 9,273,022, issued earlier this year and also derived from the original parent case, the new patent expands our ability to control the supply chain for rose bengal and related analogs for use in PV-10, PH-10 and possible successor products.”
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus’ investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements" as defined under U.S. federal securities laws. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current views of future performance, results, and trends and may be identified by their use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2015) and the following:
View source version on businesswire.com: http://www.businesswire.com/news/home/20160823005273/en/Business Wire
Last updated on: 23/08/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.